Brett K. Haumann

Brett K. Haumann

Chief Tech/Sci/R&D Officer presso ReViral Ltd.

54 anni
Health Technology
Consumer Services
Finance

Profilo

Brett K.
Haumann
is currently a Non-Executive Director at Aravax Pty Ltd., a Venture Partner at SV Health Investors LLP, and the Chief Medical Officer at ReViral Ltd.
He previously worked as the Director & Chief Medical Officer at Circassia Ltd., a Director at Reacta Biotech Ltd., the Vice President-Clinical Development & Operations at Innoviva, Inc., and the Vice President-Clinical Development at GlaxoSmithKline LLC.
He also served as a Vice President-Clinical Development & Operations at Theravance Biopharma, Inc. Dr. Haumann holds an MBA from The Open University and a doctorate from the University of the Witwatersrand.

Posizioni attive di Brett K. Haumann

SocietàPosizioneInizio
Director/Board Member 06/05/2022
Chief Tech/Sci/R&D Officer -
Private Equity Investor 01/08/2023
Tutte le posizioni attive di Brett K. Haumann

Precedenti posizioni note di Brett K. Haumann

SocietàPosizioneFine
THERAVANCE BIOPHARMA, INC. Chief Tech/Sci/R&D Officer 05/04/2021
Director/Board Member 01/11/2016
INNOVIVA, INC. Corporate Officer/Principal 01/06/2014
Chief Tech/Sci/R&D Officer 01/06/2013
Corporate Officer/Principal 01/08/2012
Vedi nel dettaglio l'esperienza di Brett K. Haumann

Formazione di Brett K. Haumann

The Open University Masters Business Admin
University of the Witwatersrand Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Brett K. Haumann

Relazioni

100 +

Relazioni di 1° grado

11

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa2
INNOVIVA, INC.

Health Technology

THERAVANCE BIOPHARMA, INC.

Health Technology

Aziende private7

Finance

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Vedi le connessioni aziendali
  1. Borsa valori
  2. Insiders
  3. Brett K. Haumann